tb-500
Thymosin-derived peptides · 17 suppliers · $3.40 to $15.60 per mg · 1 registered study · 28 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
PubChem holds this compound as CID 62707662, molecular formula C38H68N10O14, average mass 889 daltons and monoisotopic mass 888.4916 daltons, read on 2026-09-19. Those masses are computed from the deposited structure and were not measured on any material, so they are the expected value an identity check compares against rather than evidence about any vial.
The title that record carries for the CID is Unii-qhk6Z47gtg. Its synonym list runs to 32 entries. Among them: TB500, TB-500, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, TB 500, TB 500 acetate and HY-P0170.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term TB-500, read on 2026-09-19, returned 1 registered study: 1 phase 1 and 1 phase 2.
Hudson Biotech is lead sponsor on 1 of the 1 records.
On the date read, the statuses those records carried were 1 recruiting.
The earliest record the search returns is NCT07487363, first submitted 2026-03-14. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 28 records for the term TB-500 on 2026-09-19. Of those, 1 carries a clinical-trial publication type. 8 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
A Drugs@FDA query on 2026-09-19 returned no application record for any of these 3 searches:
- openfda.generic_name:"TB-500"
- openfda.substance_name:"TB-500"
- openfda.brand_name:"TB-500"
Those are results for the 3 searches printed above, and nothing wider. A compound holding an approved application under a name none of those searches covers would not answer any of them, and no dated note of which names were checked, and why those are the ones to check, is recorded here.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
No doctor prescribes this. There is no approved product under this name on the Food and Drug Administration record, read 2026-09-19, so there is no label naming who must avoid it and why.
Read this as missing information, not as a clear record. Nobody has published who is at risk, which is not the same as nobody being at risk.
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $3.40per mg | $33.9910mg | StudzPeptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-20 |
| $3.79per mg | $37.9010mg | xpeptides.comrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-20 |
| $4.20per mg | $42.0010mg | SCYRXrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-26 |
| $6.00per mg | $60.0010mg | Tex Peptidesrecord → | you can check it | Both retatrutide pages print BPC-157 identifiers verbatim, including the formula, sequence and CAS number, while the vendor's own report reads Retatrutide. The semaglutide and tirzepatide pages are correct. | single vial current priceread 2026-08-24 |
| $6.38per mg | $63.7510mg | Luxara Labsrecord → | not transcribed | not transcribed | single vial current price; listed as TB500read 2026-08-25 |
| $7.00per mg | $69.9910mg | Pepora Labsrecord → | not transcribed | not transcribed | discounted from 79.99read 2026-08-23 |
| $8.49per mg | $84.9010mg | Apex Lab Peptidesrecord → | you can check it | Two older rows still show figures their linked documents do not carry. The current 10mg and 30mg rows match their certificates on every figure. | single vial current priceread 2026-08-24 |
| $8.50per mg | $254.950.5mg × 60 vials | Swiss Chemsrecord → | not transcribed | not transcribed | capsules, 0.5mg per capsule x60read 2026-08-17 |
| $8.50per mg | $84.9910mg | Lab Trust Peptidesrecord → | not transcribed | not transcribed | single vial current price in USD, discounted from 99.99read 2026-08-26 |
| $8.50per mg | $85.0010mg | Secra Labsrecord → | you can check it | 16 of the 21 products carry no published certificate. | single vial current priceread 2026-08-24 |
| $8.50per mg | $85.0010mg | Improved Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-26 |
| $9.00per mg | $89.9910mg | Excalibur Peptidesrecord → | you can check it | Neither published retatrutide certificate names this vendor. The issuing laboratory's own register shows the accession filed against a different client, while this vendor's own certificates sit under a separate prefix. | discounted from 93.98read 2026-08-24 |
| $9.00per mg | $90.0010mg | Grey Research Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $9.00per mg | $45.005mg | Arcane Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $10.00per mg | $50.005mg | ProPeptidesrecord → | not checkable | The certificate page contains no document, no lot, no figure and no laboratory name. | single vial current priceread 2026-08-24 |
| $10.80per mg | $54.005mg | Ascension Peptidesrecord → | not transcribed | not transcribed | discounted from 60.00read 2026-08-17 |
| $15.60per mg | $78.005mg | Core Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-17 |
Read between 2026-08-17 and 2026-08-26. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-19. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-19. Formula and computed mass: PubChem, the CID printed above, read 2026-09-19. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-19.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.
- PubChem compound record, CID 62707662 read 2026-09-19